Literature DB >> 8612383

Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler.

L Molander1, E Lunell, S B Andersson, F Kuylenstierna.   

Abstract

In an open, randomized, three-way crossover study, 14 healthy smokers used one type of nicotine vapor inhaler intensely for 20 minutes every hour for 11 hours (12 administrations). Two different inhalation techniques were applied, shallow frequent sucking (buccal mode) and deep inhalations (pulmonary mode). The determination of nicotine was performed by capillary gas chromatography after single-step liquid-liquid extraction of the plasma sample. Nicotine was detected by means of a nitrogen-sensitive detector, giving high selectivity and sensitivity. The mean (+/- SD) nicotine dose released from each nicotine vapor inhaler unit was estimated at 4.00 +/- 0.60 mg (buccal mode) and 3.87 +/- 0.75 mg (pulmonary mode), inhaled with approximately 15 L of air. Mean (+/- SD) peak plasma level of the last dosing interval was 32.0 +/- 8.7 ng/ml and 34.2 +/- 8.9 ng/ml for the buccal and the pulmonary technique, respectively, achieved after 0.33 and 0.50 (median) hour, respectively. The mean (95% confidence interval [CI]) absolute bioavailability of nicotine was 51 (95% CI, 40 to 65) and 56 (95% CI, 47 to 67) when the buccal and pulmonary techniques were used, respectively. A significant correlation was found between systemically available dose and average steady-state nicotine plasma concentration. Based on the achievement of similar nicotine plasma levels, it may be concluded that the two modes of inhalation appear to be clinically equivalent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612383     DOI: 10.1016/S0009-9236(96)90107-1

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Influence of cigarette smoking on melatonin levels in man.

Authors:  Carina Ursing; Christer von Bahr; Kerstin Brismar; Sven Röjdmark
Journal:  Eur J Clin Pharmacol       Date:  2005-04-12       Impact factor: 2.953

2.  Acute effects of high-dose intragastric nicotine on mucosal defense mechanisms: an analysis of nicotine, prostaglandin E2, phospholipase A2, and phospholipids.

Authors:  G Lindell; K Bukhave; I Lilja; J R Madsen; H Graffner
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

3.  Comparison of brain nicotine uptake from electronic cigarettes and combustible cigarettes.

Authors:  Yantao Zuo; Kiran Kumar Solingapuram Sai; Alexey G Mukhin; Hannah Berg; Janiece D Morgan; Akiva Mintz; Jed E Rose
Journal:  Neuropsychopharmacology       Date:  2022-08-12       Impact factor: 8.294

Review 4.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Nicotine chemistry, metabolism, kinetics and biomarkers.

Authors:  Neal L Benowitz; Janne Hukkanen; Peyton Jacob
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Artemisinin and CYP2A6 activity in healthy subjects.

Authors:  Sara Asimus; Trinh Ngoc Hai; Nguyen Van Huong; Michael Ashton
Journal:  Eur J Clin Pharmacol       Date:  2007-12-07       Impact factor: 2.953

7.  Nicotine Population Pharmacokinetics in Healthy Smokers After Intravenous, Oral, Buccal and Transdermal Administration.

Authors:  Per O Olsson Gisleskog; Juan José Perez Ruixo; Åke Westin; Anna C Hansson; Paul A Soons
Journal:  Clin Pharmacokinet       Date:  2020-12-23       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.